Alan B Watts

US Patent:

20100183721, Jul 22, 2010

Filed:

Jan 10, 2008

Appl. No.:

12/522774

Inventors:

Robert O. Williams - Austin TX, US
Keith P. Johnston - Austin TX, US
Prapasri Sinswat - Austin TX, US
Jason T. McConville - Austin TX, US
Robert Talbert - San Antonio TX, US
Jay I. Peters - San Antonio TX, US
Alan B. Watts - Austin TX, US
True L. Rogers - Midland TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 9/14
A61K 31/436
A61P 37/00
A61P 11/00

US Classification:

424484, 514291, 977788

Abstract:

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

US Patent:

20100221343, Sep 2, 2010

Filed:

May 12, 2010

Appl. No.:

12/778795

Inventors:

Keith P. Johnston - Austin TX, US
Joshua Engstrom - Spotswood NJ, US
Jasmine Tam - Austin TX, US
Alan Watts - Plainsboro NJ, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 9/10
A61K 31/496
A61K 31/506
A61K 31/337
A61K 31/436
A61K 38/13
A61K 38/16
A61K 38/02
A61K 39/395
A61K 38/28
A61K 38/21
A61K 38/20
A61K 31/7088
A61K 31/7105
A61K 31/727
A61K 39/00
A61P 11/06
A61P 11/00
A61K 38/43

US Classification:

424484, 51425407, 514256, 514449, 514291, 514 11, 514 12, 514 2, 4241301, 514 4, 424 854, 424 852, 514 44 R, 514 44 A, 514 56, 4241841, 424 941, 977778

Abstract:

The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

US Patent:

20120077786, Mar 29, 2012

Filed:

Sep 27, 2011

Appl. No.:

13/246686

Inventors:

David A. Byron - Lawrenceville NJ, US
Alan B. Watts - Austin TX, US
Robert O. Cook - Hillsborough NJ, US
Murat Aydin - North Brunswick NJ, US

International Classification:

A61K 31/593
A61P 11/00

US Classification:

514167

Abstract:

Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.

US Patent:

20230040283, Feb 9, 2023

Filed:

Jun 9, 2022

Appl. No.:

17/836067

Inventors:

- Austin TX, US
Keith P. JOHNSTON - Austin TX, US
Prapasri SINSWAT - Austin TX, US
Jason T. MCCONVILLE - Austin TX, US
Robert TALBERT - San Antonio TX, US
Jay I. PETERS - San Antonio TX, US
Alan B. WATTS - Austin TX, US
True L. ROGERS - Midland MI, US

International Classification:

A61K 31/436
A61K 9/16
A61K 9/00
A61K 9/51
A61K 38/13
A61K 9/19

Abstract:

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

US Patent:

20210338671, Nov 4, 2021

Filed:

Jul 24, 2019

Appl. No.:

17/262313

Inventors:

- Austin TX, US
Chaeho MOON - Austin TX, US
Alan B. WATTS - Austin TX, US
John J. KOLENG - Austin TX, US

International Classification:

A61K 31/506
A61K 9/16
A61K 9/19
A61K 9/00

Abstract:

Pharmaceutical compositions which contain at less than 10% of an excipient and are presented as nanoaggregates are described herein. These pharmaceutical compositions have been shown to exhibit improved properties such as improved aerosolizability and aerodynamic performance. Also provided herein are methods of preparing the pharmaceutical compositions disclosed herein and use thereof.

US Patent:

20190269661, Sep 5, 2019

Filed:

Mar 6, 2019

Appl. No.:

16/294885

Inventors:

- Austin TX, US
Keith P. JOHNSTON - Austin TX, US
Prapasri SINSWAT - Austin TX, US
Jason T. MCCONVILLE - Austin TX, US
Robert TALBERT - San Antonio TX, US
Jay I. PETERS - San Antonio TX, US
Alan B. WATTS - Austin TX, US
True L. ROGERS - Midland MI, US

International Classification:

A61K 31/436
A61K 9/16
A61K 9/51
A61K 9/00
A61K 38/13
A61K 9/19

Abstract:

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

US Patent:

20180147161, May 31, 2018

Filed:

Sep 2, 2015

Appl. No.:

15/570828

Inventors:

- Austin TX, US
Alan WATTS - Austin TX, US
Jay PETERS - San Antonio TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 31/137
A61K 31/167
A61K 31/58
A61K 31/439
A61P 11/00
A61K 9/14
A61K 9/00

Abstract:

Dual and triple therapy combinations of drugs formulated as brittle matrix particles with a high surface area are provided herein. These particle formulations may be used in inhalation or aerosol administration techniques to provide the drug combinations to the lungs. In some aspects, these compositions may be used to treat a respiratory disease or disorder such as asthma or COPD.

US Patent:

20170165238, Jun 15, 2017

Filed:

Dec 20, 2016

Appl. No.:

15/385369

Inventors:

- Austin TX, US
Keith P. JOHNSTON - Austin TX, US
Prapasri SINSWAT - Austin TX, US
Jason T. MCCONVILLE - Austin TX, US
Robert TALBERT - San Antonio TX, US
Jay I. PETERS - San Antonio TX, US
Alan B. WATTS - Austin TX, US
True L. ROGERS - Midland MI, US

International Classification:

A61K 31/436
A61K 9/19
A61K 9/51
A61K 38/13
A61K 9/00

Abstract:

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.